Trials / Completed
CompletedNCT05337124
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 229 (actual)
- Sponsor
- Aurinia Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the United States (US).
Detailed description
This registry is an observational study designed to assess the utilization and effectiveness of LUPKYNIS in patients with lupus nephritis (LN) in the United States (US). This registry is intended to benefit and support interests of patients, clinicians, regulatory bodies, payers, and industry by obtaining longitudinal data on LUPKYNIS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LUPKYNIS | LUPKYNIS treatment per the approved US Prescribing Information |
Timeline
- Start date
- 2022-04-05
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
- First posted
- 2022-04-20
- Last updated
- 2025-06-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05337124. Inclusion in this directory is not an endorsement.